Catalyst Pharmaceuticals (CPRX) Change in Receivables (2011 - 2026)

Catalyst Pharmaceuticals has reported Change in Receivables for 9 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 24.74% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.6 million (up 453.0% YoY), and the FY2025 full-year result was $61.0 million, up 409.96% from the prior year.
• Change in Receivables for Q1 2026 stood at $4.4 million, down from $20.1 million in the prior quarter.
• The five-year high for Change in Receivables was $40.5 million in Q3 2025, with the low at -$5.4 million in Q2 2025.
• Historically, Change in Receivables has averaged $7.3 million across 5 years, with a median of $5.3 million in 2023.
• The largest YoY upside for Change in Receivables was 18466.67% in 2022 against a maximum downside of 239.65% in 2022.
• Catalyst Pharmaceuticals' Change in Receivables stood at $1.1 million in 2022, then soared by 395.92% to $5.5 million in 2023, then surged by 31.93% to $7.2 million in 2024, then soared by 178.34% to $20.1 million in 2025, then plunged by 78.29% to $4.4 million in 2026.
• The last three Change in Receivables figures came in at $4.4 million (Q1 2026), $20.1 million (Q4 2025), and $40.5 million (Q3 2025), per Business Quant data.